SpringWorks Therapeutics, Inc. Files Form 8-K with SEC on Proposed Merger Agreement

Strategic Insights -

On June 26, 2025, SpringWorks Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing its intention to adopt the Merger Agreement with Merck KGaA, Darmstadt, Germany. The proposed transaction, which is subject to certain conditions, including the approval of SpringWorks' stockholders, has generated significant interest in the biotechnology sector. The deal would see SpringWorks become a wholly-owned subsidiary of Merck KGaA, with the German company acquiring SpringWorks' product candidates and pipeline assets.

Key Takeaways:

  • SpringWorks Therapeutics, Inc. held a special meeting of stockholders on June 26, 2025, to consider and vote on the Merger Agreement Proposal, which was approved by 78.31% of represented shares.
  • Proposal 3, the Compensation Proposal, was also approved by 78.31% of represented shares, with 54,818,866 shares voting in favor and 3,955,516 shares voting against.
  • The Adjournment Proposal was not voted on as there were sufficient votes to approve the Merger Agreement Proposal.

The proposal involves the merger of EMD Holdings Merger Sub, Inc. with and into SpringWorks, with the Company surviving as a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.

Statistics:

  • 75,348,995 shares of SpringWorks Common Stock were issued and outstanding as of the close of business on May 27, 2025.
  • 59,003,420 shares of SpringWorks Common Stock were represented in person or by proxy at the Special Meeting, representing 78.31% of the shares of SpringWorks Common Stock entitled to vote.
  • The Merger Agreement Proposal was approved by the holders of 58,902,428 shares and 11,800 shares abstained.
  • Proposal 3, the Compensation Proposal, was approved by the holders of 54,818,866 shares and 3,955,516 shares voted against, with 229,038 shares abstaining.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT
  • SPRINGWORKS THERAPEUTICS, INC.'s definitive proxy statement filed with the SEC on May 28, 2025
  • SpringWorks Therapeutics, Inc.'s Form 8-K filing dated June 26, 2025.